Sanara MedTech announced that the Journal of Surgery has published a retrospective study on CellerateRX Surgical Powder titled “Activated Collagen Powder Significantly Reduces Surgical Site Infections in Patients Undergoing Elective Surgery”. About the Study and Key Results: Retrospective study of 5,335 patients undergoing elective surgeries over four years. More than a quarter of the patients received CellerateRX in evaluation of clean or clean contaminated cases. Surgical specialties included general, surgical oncology, orthopedic, vascular, neurosurgery, cardiothoracic, plastic and gynecology. The use of activated collagen in patients undergoing elective surgery resulted in a 59% reduction in surgical site infection rates. This reduction was most pronounced in the clean cases with a 69% decrease in surgical site infection rates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SMTI:
- Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
- Sanara MedTech price target lowered to $49 from $59 at Cantor Fitzgerald
- Sanara MedTech Inc. Announces Third Quarter 2023 Results
- Sanara MedTech (SMTI) Q3 Earnings Cheat Sheet
- Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
